| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/14/2023 | 660.91% | Roth MKM | → $14 | Reiterates | Buy → Buy |
| 02/22/2023 | 660.91% | Roth MKM | → $14 | Initiates Coverage On | → Buy |
What is the target price for Immix Biopharma (IMMX)?
The latest price target for Immix Biopharma (NASDAQ: IMMX) was reported by Roth MKM on August 14, 2023. The analyst firm set a price target for $14.00 expecting IMMX to rise to within 12 months (a possible 660.91% upside). 2 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Immix Biopharma (IMMX)?
The latest analyst rating for Immix Biopharma (NASDAQ: IMMX) was provided by Roth MKM, and Immix Biopharma reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Immix Biopharma (IMMX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Immix Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Immix Biopharma was filed on August 14, 2023 so you should expect the next rating to be made available sometime around August 14, 2024.
Is the Analyst Rating Immix Biopharma (IMMX) correct?
While ratings are subjective and will change, the latest Immix Biopharma (IMMX) rating was a reiterated with a price target of $0.00 to $14.00. The current price Immix Biopharma (IMMX) is trading at is $1.84, which is within the analyst's predicted range.